Skip to main content

Advertisement

SpringerLink
Log in

The Role of HMGB1 in Traumatic Brain Injury—Bridging the Gap Between the Laboratory and Clinical Studies

  • Neurotrauma (D. Sandsmark, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Traumatic brain injury (TBI) is amongst the leading causes of mortality and morbidity worldwide. However, several pharmacological strategies in the clinical setting remain unsuccessful. Mounting evidence implicates High Mobility Group Box protein 1 (HMGB1) as a unique alternative target following brain injury. Herein, we discuss current understanding of HMGB1 in TBI and obstacles to clinical translation.

Recent Findings

HMGB1 plays a pivotal role as a ‘master-switch’ of neuro-inflammation following injury and in the regulation of neurogenesis during normal development. Animal models point towards the involvement of HMGB1 signalling in prolonged activation of glial cells and widespread neuronal death. Early experimental studies demonstrate positive effects of HMGB1 antagonism on both immunohistochemical and neuro-behavioural parameters following injury. Raised serum/CSF HMGB1 in humans is associated with poor outcomes post-TBI.

Summary

HMGB1 is a promising therapeutic target post-TBI. However, further studies elucidating receptor, cell, isoform, and temporal effects are required prior to clinical translation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morbidity and mortality weekly report. 2009;58(16):421-6.

  2. Ghawami H, Sadeghi S, Raghibi M, Rahimi-Movaghar V. Executive functioning of complicated-mild to moderate traumatic brain injury patients with frontal contusions. Appl Neuropsychol Adult. 2016:1–9. https://doi.org/10.1080/23279095.2016.1157078.

  3. Nygren DeBoussard C, Lannsjo M, Stenberg M, Stalnacke BM, Godbolt AK. Behavioural problems in the first year after severe traumatic brain injury: a prospective multicentre study. Clin Rehabil. 2017;31(4):555–66. https://doi.org/10.1177/0269215516652184.

    Article  PubMed  Google Scholar 

  4. Lewis FD, Horn GJ. Depression following traumatic brain injury: impact on post-hospital residential rehabilitation outcomes. Neuro Rehabilit. 2017. https://doi.org/10.3233/NRE-161427.

  5. Chan RC, Hoosain R, Lee TM, Fan YW, Fong D. Are there sub-types of attentional deficits in patients with persisting post-concussive symptoms? A cluster analytical study. Brain Inj. 2003;17(2):131–48. https://doi.org/10.1080/0269905021000010168.

    Article  PubMed  Google Scholar 

  6. Simon DW, McGeachy MJ, Bayır H, Clark RSB, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nature Rev Neurol. 2017;13(9):572. https://doi.org/10.1038/nrneurol.2017.116.

    Article  Google Scholar 

  7. Jassam YN, Izzy S, Whalen M, McGavern DB, El Khoury J. Neuroimmunology of traumatic brain injury: time for a paradigm shift. Neuron. 2017;95(6):1246–65. https://doi.org/10.1016/j.neuron.2017.07.010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bianchi ME, Crippa MP, Manfredi AA, Mezzapelle R, Rovere Querini P, Venereau E. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev. 2017;280(1):74–82. https://doi.org/10.1111/imr.12601.

    Article  CAS  PubMed  Google Scholar 

  9. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270(43):25752–61. https://doi.org/10.1074/jbc.270.43.25752.

    Article  CAS  PubMed  Google Scholar 

  10. Ueda T, Yoshida M. HMGB proteins and transcriptional regulation. Biochimica et Biophysica Acta. 2010;1799(1-2):114–8. https://doi.org/10.1016/j.bbagrm.2009.11.005.

    Article  CAS  PubMed  Google Scholar 

  11. Fink MP. Bench-to-bedside review: high-mobility group box 1 and critical illness. Crit Care (London, England). 2007;11(5):229. https://doi.org/10.1186/cc6088.

    Article  Google Scholar 

  12. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, et al. High mobility group 1 B-box mediates activation of human endothelium. J Internal Med. 2003;254(4):375–85. https://doi.org/10.1046/j.1365-2796.2003.01204.x.

    Article  CAS  PubMed  Google Scholar 

  13. He M, Bianchi ME, Coleman TR, Tracey KJ, Al-Abed Y. Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance. Mol Med. 2018;24(1):21. https://doi.org/10.1186/s10020-018-0023-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. •• Manivannan S, Marei O, Elalfy O, Zaben M. Neurogenesis after traumatic brain injury - The complex role of HMGB1 and neuroinflammation. Neuropharmacology. 2021;183:108400. https://doi.org/10.1016/j.neuropharm.2020.108400Narrative review summarising the dual role of HMGB1 in brain injury and neurogenesis. Effects of concentration, context, HMGB1 isoforms, and target receptors are discussed.

    Article  CAS  PubMed  Google Scholar 

  15. Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clinica Chimica Acta; Int J Clin Chem. 2012;413(21-22):1737–41. https://doi.org/10.1016/j.cca.2012.07.002.

    Article  CAS  Google Scholar 

  16. Au AK, Aneja RK, Bell MJ, Bayir H, Feldman K, Adelson PD, et al. Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome C predict outcome after pediatric traumatic brain injury. J Neurotrauma. 2012;29(11):2013–21. https://doi.org/10.1089/neu.2011.2171.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–5. https://doi.org/10.1038/nature00858.

    Article  CAS  PubMed  Google Scholar 

  18. Laird MD, Shields JS, Sukumari-Ramesh S, Kimbler DE, Fessler RD, Shakir B, et al. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia. 2014;62(1):26–38. https://doi.org/10.1002/glia.22581.

    Article  PubMed  Google Scholar 

  19. •• Manivannan S, Harari B, Muzaffar M, Elalfy O, Hettipathirannahelage S, James Z, et al. Glycyrrhizin Blocks the Detrimental Effects of HMGB1 on Cortical Neurogenesis After Traumatic Neuronal Injury. Brain Sci. 2020;10(10):760. https://doi.org/10.3390/brainsci10100760In vitro study demonstrating that HMGB1 release following traumatic injury reduces neuronal numbers/proportions in primary neural stem cell/progenitor cultures via RAGE-dependent effect. Indicates that HMGB1 release post-TBI may hinder cortical neurogenesis.

    Article  CAS  PubMed Central  Google Scholar 

  20. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem. 2007;103(2):590–603. https://doi.org/10.1111/j.1471-4159.2007.04788.x.

    Article  CAS  PubMed  Google Scholar 

  21. Braun M, Vaibhav K, Saad NM, Fatima S, Vender JR, Baban B, et al. White matter damage after traumatic brain injury: a role for damage associated molecular patterns. Biochim Biophys Acta Mol Basis Dis. 2017;1863(10 Pt B):2614–26. https://doi.org/10.1016/j.bbadis.2017.05.020.

    Article  CAS  PubMed  Google Scholar 

  22. Chen X, Wu S, Chen C, Xie B, Fang Z, Hu W, et al. Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-kappaB pathway following experimental traumatic brain injury. J Neuroinflammation. 2017;14(1):143. https://doi.org/10.1186/s12974-017-0917-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22(20):5551–60. https://doi.org/10.1093/emboj/cdg516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gao T, Chen Z, Chen H, Yuan H, Wang Y, Peng X, et al. Inhibition of HMGB1 mediates neuroprotection of traumatic brain injury by modulating the microglia/macrophage polarization. Biochem Biophys Res Commun. 2018;497(1):430–6. https://doi.org/10.1016/j.bbrc.2018.02.102.

    Article  CAS  PubMed  Google Scholar 

  25. Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, et al. Microglial and macrophage polarization—new prospects for brain repair. Nature Rev Neurol. 2015;11(1):56–64. https://doi.org/10.1038/nrneurol.2014.207.

    Article  Google Scholar 

  26. Wang L, Wu J, Guo X, Huang X, Huang Q. RAGE plays a role in LPS-induced NF-κB activation and endothelial hyperpermeability. Sensors (Basel, Switzerland). 2017;17(4):722. https://doi.org/10.3390/s17040722.

    Article  CAS  Google Scholar 

  27. Okuma Y, Liu K, Wake H, Liu R, Nishimura Y, Hui Z, et al. Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction. Neuropharmacology. 2014;85:18–26. https://doi.org/10.1016/j.neuropharm.2014.05.007.

    Article  CAS  PubMed  Google Scholar 

  28. Okuma Y, Liu K, Wake H, Zhang J, Maruo T, Date I, et al. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol. 2012;72(3):373–84. https://doi.org/10.1002/ana.23602.

    Article  CAS  PubMed  Google Scholar 

  29. Pang H, Huang T, Song J, Li D, Zhao Y, Ma X. Inhibiting HMGB1 with glycyrrhizic acid protects brain injury after DAI via its anti-inflammatory effect. Mediators Inflamm. 2016;2016:4569521. https://doi.org/10.1155/2016/4569521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Nishibori M, Wang D, Ousaka D, Wake H. High mobility group box-1 and blood-brain barrier disruption. Cells. 2020;9(12):2650. doi:https://doi.org/10.3390/cells9122650.

  31. Chou DK, Zhang J, Smith FI, McCaffery P, Jungalwala FB. Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration. J Neurochem. 2004;90(6):1389–401. https://doi.org/10.1111/j.1471-4159.2004.02609.x.

    Article  CAS  PubMed  Google Scholar 

  32. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000;275(51):40096–105. https://doi.org/10.1074/jbc.M006993200.

    Article  CAS  PubMed  Google Scholar 

  33. Xue X, Chen X, Fan W, Wang G, Zhang L, Chen Z, et al. High-mobility group box 1 facilitates migration of neural stem cells via receptor for advanced glycation end products signaling pathway. Scientific Reports. 2018;8(1):4513. https://doi.org/10.1038/s41598-018-22672-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Okuma Y, Wake H, Teshigawara K, Takahashi Y, Hishikawa T, Yasuhara T, et al. Anti-high mobility group box 1 antibody therapy may prevent cognitive dysfunction after traumatic brain injury. World Neurosurg. 2019;122:e864–e71. https://doi.org/10.1016/j.wneu.2018.10.164.

    Article  PubMed  Google Scholar 

  35. Su X, Wang H, Zhao J, Pan H, Mao L. Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-kappaB pathway after traumatic brain injury in the rat. Mediators Inflammation. 2011;2011:807142. https://doi.org/10.1155/2011/807142.

    Article  CAS  Google Scholar 

  36. Evran S, Calis F, Akkaya E, Baran O, Cevik S, Katar S, et al. The effect of high mobility group box-1 protein on cerebral edema, blood-brain barrier, oxidative stress and apoptosis in an experimental traumatic brain injury model. Brain Res Bull. 2020;154:68–80. https://doi.org/10.1016/j.brainresbull.2019.10.013.

    Article  CAS  PubMed  Google Scholar 

  37. Gu XJ, Xu J, Ma BY, Chen G, Gu PY, Wei D, et al. Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism. Chin J Traumatol = Zhonghua chuang shang za zhi. 2014;17(1):1–7.

    CAS  PubMed  Google Scholar 

  38. Aneja RK, Alcamo AM, Cummings J, Vagni V, Feldman K, Wang Q, et al. Lack of benefit on brain edema, blood-brain barrier permeability, or cognitive outcome in global inducible high mobility group box 1 knockout mice despite tissue sparing after experimental traumatic brain injury. J Neurotrauma. 2019;36(2):360–9. https://doi.org/10.1089/neu.2018.5664.

    Article  PubMed  Google Scholar 

  39. Armstrong RC, Mierzwa AJ, Sullivan GM, Sanchez MA. Myelin and oligodendrocyte lineage cells in white matter pathology and plasticity after traumatic brain injury. Neuropharmacology. 2016;110(Pt B):654–9. https://doi.org/10.1016/j.neuropharm.2015.04.029.

    Article  CAS  PubMed  Google Scholar 

  40. •• Ved R, Sharouf F, Harari B, Muzaffar M, Manivannan S, Ormonde C, et al. Disulfide HMGB1 acts via TLR2/4 receptors to reduce the numbers of oligodendrocyte progenitor cells after traumatic injury in vitro. Sci Rep. 2021;11(1):6181. https://doi.org/10.1038/s41598-021-84932-0Seminal in vitro study demonstrating a detrimental effect of HMGB1 on oligodendrocyte progenitor cells via TLR2/4 following traumatic injury. Indicates that extensive HMGB1 release post-injury may hinder recovery through impaired white matter repair.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gao TL, Yuan XT, Yang D, Dai HL, Wang WJ, Peng X, et al. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury. J Trauma Acute Care Surg. 2012;72(3):643–9. https://doi.org/10.1097/TA.0b013e31823c54a6.

    Article  CAS  PubMed  Google Scholar 

  42. Hung CH, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, et al. A randomized controlled trial of glycyrrhizin plus tenofovir vs. tenofovir in chronic hepatitis B with severe acute exacerbation. Clin Transl Gastroenterol. 2017;8(6):e104. https://doi.org/10.1038/ctg.2017.29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Xu W, Li Y, Ju M, Lai W, Lu X, Shi H, et al. A multicenter, randomized, double-blind, placebo-controlled study of compound glycyrrhizin capsules combined with a topical corticosteroid in adults with chronic eczema. Evid Based Complement Alternat Med. 2020;2020:6127327. https://doi.org/10.1155/2020/6127327.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regulatory Toxicol Pharmacol: RTP. 2006;46(3):167–92. https://doi.org/10.1016/j.yrtph.2006.06.002.

    Article  CAS  PubMed  Google Scholar 

  45. Lin C-C, Weng M-T, Chung C-S, Liang C-C. The dramatic effect of intravenous glycyrrhizin on acute-on-chronic hepatic failure in chronic hepatitis B patients without liver cirrhosis. Advances Digestive Med. 2019;6(4):153–7. https://doi.org/10.1002/aid2.13131.

    Article  Google Scholar 

  46. Sims CA, Wattanasirichaigoon S, Menconi MJ, Ajami AM, Fink MP. Ringer’s ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Critic Care Med. 2001;29(8):1513–8. https://doi.org/10.1097/00003246-200108000-00003.

    Article  CAS  Google Scholar 

  47. Shin JH, Kim ID, Kim SW, Lee HK, Jin Y, Park JH, et al. Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium. Mol Med. 2015;20(1):649–57. https://doi.org/10.2119/molmed.2014.00039.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Shi H, Wang HL, Pu HJ, Shi YJ, Zhang J, Zhang WT, et al. Ethyl pyruvate protects against blood-brain barrier damage and improves long-term neurological outcomes in a rat model of traumatic brain injury. CNS Neurosci Therapeutics. 2015;21(4):374–84. https://doi.org/10.1111/cns.12366.

    Article  CAS  Google Scholar 

  49. Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. J Internal Med. 2007;261(4):349–62. https://doi.org/10.1111/j.1365-2796.2007.01789.x.

    Article  CAS  PubMed  Google Scholar 

  50. Yang L, Wang F, Yang L, Yuan Y, Chen Y, Zhang G, et al. HMGB1 a-box reverses brain edema and deterioration of neurological function in a traumatic brain injury mouse model. Cell Physiol Biochem. 2018;46(6):2532–42. https://doi.org/10.1159/000489659.

    Article  CAS  PubMed  Google Scholar 

  51. Walker D, Lue LF, Paul G, Patel A, Sabbagh MN. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24(3):393–9. https://doi.org/10.1517/13543784.2015.1001490.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Availability of Data and Material

N/A

Code Availability

N/A

Funding

Dr. Malik Zaben is a member of the BRAIN Unit, which is funded by the Welsh Government through Health and Care Research Wales.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Southampton General Hospital, Southampton, UK

    S Manivannan

  2. School of Medicine, Cardiff University, Cardiff, UK

    E Wales

  3. Department of Neurosurgery, University Hospital of Wales, Heath Park Way, Cardiff, CF14 4XW, UK

    M Zaben

  4. Brain Repair & Intracranial Neurotherapeutics (BRAIN) Unit, Cardiff University, Cardiff, UK

    M Zaben

Authors
  1. S Manivannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Wales
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Zaben
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Zaben.

Ethics declarations

This manuscript has been written in compliance with the ethical standards of Current Neurology and Neuroscience Reports.

Conflict of Interest

None

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neurotrauma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manivannan, S., Wales, E. & Zaben, M. The Role of HMGB1 in Traumatic Brain Injury—Bridging the Gap Between the Laboratory and Clinical Studies. Curr Neurol Neurosci Rep 21, 75 (2021). https://doi.org/10.1007/s11910-021-01158-3

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11910-021-01158-3

Keywords

Search

Navigation